AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

6-Shogaol, an active constituent of ginger, inhibits breast cancer cell invasion. – GreenMedInfo Summary

 Uncategorized  Comments Off on 6-Shogaol, an active constituent of ginger, inhibits breast cancer cell invasion. – GreenMedInfo Summary
Aug 042013
 

File:Shogaol.png

6-Shogaol, an active constituent of ginger, inhibits breast cancer cell invasion by reducing matrix metalloproteinase-9 expression via blockade of nuclear factor-κB activation.

Abstract Source:

Br J Pharmacol. 2010 Dec ;161(8):1763-77. PMID: 20718733

Abstract Author(s):

H Ling, H Yang, S-H Tan, W-K Chui, E-H Chew

Article Affiliation:

Department of Pharmacy, National University of Singapore, Singapore, Singapore.

Abstract:

BACKGROUND AND PURPOSE: Shogaols are reported to possess anti-inflammatory and anticancer activities. However, the antimetastatic potential of shogaols remains unexplored. This study was performed to assess the effects of shogaols against breast cancer cell invasion and to investigate the underlying mechanisms.

http://www.greenmedinfo.com/article/6-shogaol-active-constituent-ginger-inhibits-breast-cancer-cell-invasion

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010581/

Shogaol, also known as (6)-shogaol, is a pungent constituent of ginger similar in chemical structure to gingerol. Likezingerone, it is produced when ginger is dried or cooked.

Shogaols are artifacts formed during storage or through excess heat, probably created by a dehydration reaction of the gingerols. The ratio of shogaols to gingerols sometimes is taken as an indication of product quality.

The name ‘shogaol’ is derived from the Japanese name for ginger (生姜、shōga).

Shogaol is rated 160,000 SHU on Scoville scale. When compared to other pungent compounds, shogaol is moderately more pungent than piperine, but less than capsaicin.

  1. McGee, Harold (2004). On Food and Cooking: The Science and Lore of the Kitchen (2nd ed.). New York: Scribner pp. 425-426.
  2. NSF International Determination of Gingerols and Shogaols in Zingiber officinale rhizome and powdered extract by High-Performance Liquid Chromatography.
  3. Ula (1996), op. cit. “The HPLC measures the capsaicinoid(s) in ppm, which can then be converted to Scoville units using a conversion factor of 15, 20 or 30 depending on the capsaicinoid.” This would make capsaicin 15,000,000 SHU

 

more info

6-Shogaol

A bioactive ingredient of ginger root (Zingiber officinale), a medicinal plant having anti-nausea, anti-inflammatory, and anti-carcinogenic properties and a carminative effect

 

  • Catalog No: APH-02034
  • CAS Number: 555-66-8
  • Chemical Formula: C17H24O3
  • Molecular Weight: 276.37
  • Purity: > 95% determined by HPLC
  • Appearance: Viscous yellow liquid
  • Solubility: Soluble in methanol and ethanol
  • Stability: Unstable at room temperature in the presence of oxygen and light. Stable over extended period at -20°C.
  • Storage: -20°C
  • Shipping: On ice (5°C)
  • Handling: Avoid exposure to oxygen and direct sunlight

6-Gingerol Ginger-Rhizomes6-Shogaol is isolated from the dried or cooked rhizomes or roots of the plant Zingiber officinale (ginger). It is a perennial reed-like plant with annual leafy stems, about a meter (3 to 4 feet) tall. 6-Shogaol is a dehydrated 6-gingerol molecule that has lost a molecule of water during the drying or cooking process.

Ginger produces clusters of white and pink flower buds that bloom into yellow flowers. Because of its aesthetic appeal and the adaptation of the plant to warm climates, ginger is often used as landscaping around subtropical homes. Traditionally, the root is gathered when the stalk withers; it is immediately dried, scalded, or washed and scraped, to kill it and prevent sprouting.

6-Shogaol is isolated from dried or cooked ginger root using ethanol and other organic solvents followed by chromatographic purification. Aphios isolates 6-shogaol utilizing near-critical and supercritical fluids using CXF and CXP enabling technology platforms as alternatives to ethanol and conventional organic solvents techniques.

Biological Activity:

Ginger (Zingiber officinale RoscoeZingiberaceae) is a medicinal plant that has been widely used in Chinese, Ayurvedic and other global herbal medicinal practices since ancient times for a wide array of ailments including arthritis, rheumatism, sprains, muscular aches, pains, sore throats, cramps, constipation, indigestion, vomiting, hypertension, dementia, fever, infectious diseases and helminthiasis (Ali et al., 2008).

Ginger has been approved for use by Germany’s Commission E, the agency responsible for regulating the use of herbal products in that country (Blumenthal, 1998). Ginger has recently been studied scientifically for its effect on nausea and vomiting associated with motion sickness, surgery, pregnancy and cancer chemotherapy.

There may be several mechanisms of action in play relative to the antiemetic properties of ginger. It has been reported that the antiemetic qualities may be derived from ginger’s anti-serotonin 3 effects on the gastrointestinal and central nervous system (Chaiyakunapruk et al., 2006). In a study of guinea pig ileum, it was found that certain ingredients of ginger (6-, 8- and 10-gingerols) inhibit the anti-serotonin 3 receptor function (Huang et al., 1991 and Yamahara et al., 1989). In addition, these active ingredients have been shown to affect gastric motility and potentially have an antispasmodic effect on the gastrointestinal system (Hashimoto et al., 2002 and Suekawa et al., 1984).

Pan et al. (2008) investigated the inhibitory effects of 6-shogaol and a related compound, 6-gingerol, on the induction of nitric oxide synthase (NOS) and cyclooxygenase-2 (COX-2) in murine RAW 264.7 cells activated with LPS. Their results show that 6-shogaol downregulates inflammatory iNOS and COX-2 gene expression in macrophages by inhibiting the activation of NF-κB by interfering with the activation PI3K/Akt/I κB kinases IKK and MAPK.

References:

Ali B, Blunden G, Tanira M and Nemmar A. (2008). Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): A review of recent research. Food and Chemical Toxicology. 46(2): 409-420.

Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Klein S, Riggins C and Rister R. (1998). The Complete German Commission E monographs. Therapeutic Guide to Herbal Medicines, Austin TX, American Botanical Council.

Chaiyakunapruk N, Kitikannakorn N, Nathisuwan S, Leeprakobboon K and Leelasettagool C. (2006). The efficacy of ginger for the prevention of postoperative nausea and vomiting: a meta-analysis. Am. J. Obstet. Gynecol. 194, 95–99.

Chen C, Kuo M, Wu C and Ho C. (1986). Pungent Compounds of Ginger (Zingiber officinale Roscoe) Extracted by Liquid Carbon Dioxide. Journal of Agriculture and Food Chemistry 34(3): 477-480.

Hashimoto K, Satoh K, Murata P, Makino B, Sakakibara I, Kase Y, Ishige A, Higuchi M and Sasaki H. (2002). Component of Zingiber officinale that improves the enhancement of small intestinal transport. Planta Medica. 68:936-9.

Huang Q, Iwamoto M, Aoki S, Tanaka N, Tajima K, Yamahara J, Takaishi Y, Yoshida M, Tomimatsu T and Tamai Y. (1991). Anti-5-hydroxytryptamine 3 effect of galanolactone, diterpenoid isolated from ginger. Chem. Pharm. Bull. (Tokyo) 39, 397–399.

Pan M, Hsieh M, Hsu P, Ho S, Lai C, Wu H, Sang S and Ho C. (2008). 6-Shogaol suppressed lipopolysaccharide-induced up-expression of iNOS and COX-2 in murine macrophages. Mol Nutr Food Res. 52(12):1467-77.

Suekawa M, Ishige A, Yuasa K, Sudo K, Aburada M and Hosoya E. (1984). Pharmacological studies on ginger: I. Pharmacological action of pungent constituents, (6)-gingerol and (6)-shogaol. J Pharmacobiodyn. 7:836-48.

Yamahara J, Rong H, Iwamoto M, Kobayashi G, Matsuda H and Fujimura H. (1989). Active components of ginger exhibiting anti-serotonergic action. Phytother. Res. 3, 70–71.

Share

ALL ABOUT ANTIDIABETIC PLANT: COCCINIA INDICA

 Uncategorized  Comments Off on ALL ABOUT ANTIDIABETIC PLANT: COCCINIA INDICA
Aug 032013
 

Introduction
Plants had been used for medicinal purposes long before recorded history. Ancient Chinese and Egyptian papyrus writings describe medicinal uses for plants as early as 3,000 BC. Indigenous cultures (such as African and Native American) used herbs in their healing rituals, while others developed traditional medical systems (such as Ayurveda and Traditional Chinese Medicine) in which herbal therapies were used;…………………………..

read all at

http://www.pharmatutor.org/articles/all-about-antidiabetic-plant-coccinia-indica

Share

Indian biopharma giant Biocon clocks revenue worth $121 mn

 companies, Uncategorized  Comments Off on Indian biopharma giant Biocon clocks revenue worth $121 mn
Jul 302013
 

 

Kiran Mazumdar-Shaw, chairman and managing director, Biocon.

Indian biopharma giant Biocon reported healthy growth of 22 percent for Q1 FY14 riding on the back of an increased geographical footprint in the emerging markets

 

Bangalore: Indian biopharma giant Biocon reported healthy growth of 22 percent for Q1 FY14. The firm clocked revenues worth $121 million (Rs723 crore), EBITDA of $29.50 million (Rs175 crore); and profit after tax (PAT) of $15.80 million (Rs94 crore).

Read more at: http://www.biospectrumasia.com/biospectrum/news/192549/how-biocon-clock-revenue-worth-usd121-mn#.UfdqX6I3CSo

biocon-s-india-focused-branded-formulations-vertical-as-well-as-research-services-continue-to-grow-at-a-steady-pace

Biocon’s India-focused branded formulations vertical as well as research services continue to grow at a steady pace

Share

B Family Album -Structural Biology: First structures of class B G protein-coupled receptors may aid drug hunts

 Uncategorized  Comments Off on B Family Album -Structural Biology: First structures of class B G protein-coupled receptors may aid drug hunts
Jul 292013
 
Two new G-Protein Coupled Receptor structures, the glucagon receptor (computer model with extracellular domain) and corticotropin-releasing factor receptor, showing their location on the GPCR family tree.

A computer model of a full-length glucagon receptor (left) and a crystal structure of a corticotropin-releasing factor receptor (right) add details of class B receptors to the class A structures already on the GPCR family tree.
Credit: Katya Kadyshevskaya
As many as 30% of drugs on the market target G protein-coupled receptors (GPCRs), a family of signaling conduits that snake back and forth across cell membranes. But there are several classes of these proteins, and scientists’ knowledge of the structures is almost entirely restricted to just one, the class A subtype. So drugs could be missing a lot of targets. Aim could improve, however, now that researchers have the first two reports of class B GPCR structures (Nature 2013, DOI: 10.1038/nature12357 and10.1038/nature12393
read all at
Share

Tesaro begins phase III trial of niraparib for treatment of ovarian cancer

 Uncategorized  Comments Off on Tesaro begins phase III trial of niraparib for treatment of ovarian cancer
Jul 292013
 

niraparib

  MK-4827

MK-4827 Formula: C19H20N4O 
 
MK-4827 Storage: at -20 ℃ 2 years 
MK-4827 CAS No.: 1038915-60-4

MK-4827 is an inhibitor of PARP 1 and 2 with IC50 = 3.8 and 2.1 nM, respectively, currently in clinical trials. In a whole cell assay, it inhibited PARP activity with EC50 = 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range. MK-4827 was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer

TESARO, Inc.  an oncology-focused biopharmaceutical company, today announced that it has initiated patient enrollment in a Phase 3 trial of niraparib, an inhibitor of poly ADP-ribose polymerase (PARP), for the treatment of ovarian cancer. This trial, referred to as NOVA, will evaluate a single daily 300 milligram dose of niraparib in 360 patients with high grade serous, platinum sensitive, relapsed ovarian cancer compared to placebo.
Read more: 

http://www.benzinga.com/news/13/07/3773861/tesaro-initiates-phase-3-trial-of-niraparib-for-treatment-of-patients-with-ovaria?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+benzinga+%28Benzinga+News+Feed%29

Biological Activity of MK-4827:
MK-4827 is a potent, selective, PARP 1/2 inhibitor with IC50 of 3.8 and 2.1 nM for PARP1 and 2, respectively. MK-4827 possesses potential antineoplastic activity. In a whole cell assay, MK-4827 prevented PARP activity with an EC50 of 4 nM, enhancing the accumulation of DNA strand breaks and promoting genomic instability and apoptosis. MK-4827 induces selective synthetic lethality in homologous recombination (HR) repair deficient tumors with BRCA1 / 2 loss and tumor cell lines with non-BRCA-related HR defects, supporting clinical utility in sporadic tumors. MK-4827 reveals good pharmacokinetic properties and is currently in phase I clin. trials. The phase I clinical trials for MK-4827 is ongoing in the treatment of solid tumors.
References on MK-4827:
1. Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1).2. A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8).

3. PARP inhibitor MK4827
Abstract 
An inhibitor of Poly (ADP-ribose) polymerase (PARP) with potential Antineoplastic Activity. PARP Inhibitor MK4827 inhibits PARP Activity, ENHANCING the accumulation of DNA Strand Breaks and promoting genomic instability and apoptosis. The PARP family of Proteins detect and repair single strand DNA breaks by the base-excision repair (BER) pathway.

4. Glendenning J, Tutt A. PARP inhibitors – Current Status and the Walk towards Early Breast cancer. Breast. 2011 Oct; 20 Suppl 3: S12-9.
Abstract 
… Early Phase Trials with efficacy endpoints have been presented for the PARP inhibitors AG014699, olaparib, veliparib, iniparib and MK4827. The results of the first phase II trials exploring monotherapy PARP inhibitor strategies, which are based on revisiting the concept of synthetic lethality, have emerged and are reviewed herein. The clinical trials that have or are exploring combinations with DNA damaging therapy in these contexts are discussed with particular reference to breast cancer, as are biomarkers that have been proposed and are being investigated to develop optimal drug schedule and patient selection criteria for these DNA repair targeting approaches.

5. Jones, Philip; Altamura, Sergio; Boueres, Julia et al. Discovery of 2 – {4 – [(3S)-Piperidin-3-yl] phenyl}-2H-INDAZOLE-7-carboxamide (MK-4827): A Novel Oral Poly (ADP-ribose) polymerase (PARP) Inhibitor efficacious in BRCA-1 and -2 Mutant Tumors. Journal of Medicinal Chemistry (2009), 52 (22), 7170-7185.
Abstract 
… We Disclose the Development of a novel series of 2-phenyl-2H-indazole-7-carboxamides as poly (ADP-ribose) polymerase (PARP) 1 and 2 inhibitors. This series was optimized to improve enzyme and cellular activity, and the resulting PARP inhibitors display antiproliferation activities against BRCA-1 and BRCA-2 deficient cancer cells, with high selectivity over BRCA proficient cells. Extrahepatic oxidation by CYP450 1A1 and 1A2 was identified as a metabolic concern, and strategies to improve pharmacokinetic properties are reported. These efforts culminated in the identification of 2 – {4 – [(3S)-piperidin-3-yl] phenyl}-2H-indazole-7-carboxamide 56 (MK-4827), which displays good pharmacokinetic properties and is currently in phase I clinical trials. This compound displays excellent PARP 1 and 2 inhibition with IC50 = 3.8 and 2.1 nM, respectively, and in a whole cell assay, it inhibited PARP activity with EC50 = 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10? 100 nM range. Compound 56 was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.

Share
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: